Gilead Sciences Inc (GILD)

[north40000]

"NASH would likely be affecting many if not most of those who should be on Vascepa anyway. "IF" Vascepa can be proven effective in treating or preventing NASH it would be something that BP could really exploit in future years, as NASH is not just a US problem but a worldwide problem that is only going to get worse."


The following was in the supplementary appendix for R-IT...


Prespecified List of Additional Exploratory Analyses

The following list presents additional pre-specified exploratory efficacy analyses that could be of particular interest to the general clinical and scientific community:

Non-alcoholic fatty liver disease (NAFLD) analyses using NAFLD Fibrosis Score (NFS), assessing - ITT Population:

- Effect on primary and key secondary composite endpoints by baseline NFS category, and,

- Treatment effect on change from baseline in NFS at 1 and 5 years


It appears that this is on Amarin's radar, but no data R-IT has been released as of yet with regards to NAFLD.